GlassScriptPhysician profile
Anas Entabi
NPI 1669465258
$8,808.67
in general payments reported to CMS, 2019-2025
41 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $1,299 · 2021: $1,731 · 2022: $1,209 · 2023: $1,046 · 2024: $1,155 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406 · Education: $95.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.73 |
| Education | $95.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,610.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,219.56 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $876.46 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $638.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $555.21 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $456.65 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $366.64 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $286.49 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $277.34 | 2019-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $227.41 | 2024-2025 | Voquezna |
| Abbvie INC. | $195.45 | 2019-2025 | |
| Abbott Laboratories | $184.87 | 2020-2023 | Freestyle Libre 3 |
| Pfizer INC. | $182.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $172.94 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $158.02 | 2022-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Entabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.